Telehealth Groups May Improve the Social Lives of Young Cancer Populations

Fact checked by Russ Conroy
News
Article

Most patients with cancer who took part in a telehealth group expressed that they liked the members of their group and felt less social isolation.

Overall, 39% reported feeling very satisfied with their experience in the telehealth group, 44% reported feeling satisfied, and 17% reported feeling somewhat satisfied.

Overall, 39% reported feeling very satisfied with their experience in the telehealth group, 44% reported feeling satisfied, and 17% reported feeling somewhat satisfied.

Telehealth group intervention demonstrated the potential to decrease social isolation as a feasible, acceptable, and preferred alternative over in-person groups in adolescents and young adults (AYAs) with cancer, according to findings from a feasibility pilot study presented in a poster session at the 2025 American Psychosocial Oncology Society Meeting.

Of the patients who completed the acceptability measure (n = 18), 78% strongly agreed that they would recommend the telehealth group, 17% somewhat agreed, and 6% somewhat disagreed; 83% strongly agreed that they liked their group leader and 17% somewhat agreed; 83% strongly agreed that they liked their group members, 11% somewhat agreed, and 6% neither agreed nor disagreed. Additionally, 61% strongly agreed that the group was helpful, 33% somewhat agreed, and 6% neither agreed nor disagreed; 61% strongly agreed they felt less isolated or alone, 33% somewhat agreed, and 6% strongly disagreed.

Overall, 39% reported feeling very satisfied with their experience in the telehealth group, 44% reported feeling satisfied, and 17% reported feeling somewhat satisfied. Additionally, 70% of patients preferred telehealth groups, 14% preferred in-person groups, and 16% had no preference.

“[AYAs] with cancer report feeling socially isolated and express desire for peer support groups,” lead study investigator Sherilynn Chan, PhD, from the Seattle Children’s Hospital and the University of Washington, stated in the poster. “Findings suggest the telehealth group intervention is feasible, acceptable, preferred over in-person groups, and has potential to decrease social isolation.”

A total of 37 patients between 14 and 35 years (mean, 19.7; SD, 4.86) who were in the High School and AYA Cancer Group participated in the trial; the groups were offered twice annually and consisted of 6 to 8 weekly sessions. Those who were AYAs who were on or had received treatment for cancer, brain tumors, or medical conditions requiring hematopoietic stem cell transplant were assigned to the High School Group or AYA Group. Additionally, 51% of patients were female, and 73% were White.

The trial’s objectives were to evaluate the feasibility and acceptability of an existing telehealth peer support group intervention, conduct patient stakeholder interviews, and administer exploratory measures of patient-reported outcomes both before and after intervention. Feasibility was described as enrollment, attendance, and attrition.

Groups met for a total of 6 to 8 weekly sessions; 43% of patients attended 6 to 8 sessions, 41% attended 1 to 2 sessions, and 16% of patients attended 3 to 4 sessions. Of the 49 patients who were scheduled to participate, 37 attended at least 1 session; the most cited reason for absence was medical appointments, and 3 patients withdrew from the groups.

The authors noted that there was 100% pre-intervention and 85.7% post-measure completion for patient-reported outcomes, indicating that the study procedures were feasible. The study also included a preliminary analysis of 12 interviews conducted with patients who participated in the groups.

One patient from a group said, “I just really enjoyed the people in the group. I really enjoyed asking questions of others. I felt affirmed in the stories that I would tell and the experiences I had felt validated. Regardless of how good or bad they were, it just felt nice to be able to share with a group of people who just got it, who understood it.”

Another stated, “There were occasions where I was kind of feeling down coming into it, you know, maybe a bad day at school or something and I feel like I left each of the sessions with a smile on my face…I think it was a nice environment and kind of a safe space that uplifted me a bit.”

The small sample size and number of missed sessions limiting exposure to the intervention were cited as limitations of the study.

Reference

Chan S, Patten J, Lau N. Telehealth group intervention for adolescents and young adults with cancer: a feasibility pilot study. Presented at the 2025 American Psychosocial Oncology Society Meeting; March 5-7, 2025, Pittsburgh, PA. Poster W2.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content